ASCO 2023 Breast Cancer

CME

Key Studies in Breast Cancer: Independent Conference Coverage of the 2023 ASCO Annual Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 18, 2023

Expiration: August 17, 2024

Erika P. Hamilton
Erika P. Hamilton, MD
Sara M. Tolaney
Sara M. Tolaney, MD, MPH

Activity

Progress
1
Course Completed

Introduction

In this activity, Sara Tolaney, MD, MPH, and Erika Hamilton, MD, review key studies in breast cancer presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, with a focus on the clinical implications of new data.

Please note that the slide thumbnails in this activity link to PowerPoint slidesets, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional (HCP), how many patients with breast cancer do you provide care for in a typical month?

Which of the following best approximates the absolute invasive disease–free survival (iDFS) benefit at 3 years with adjuvant ribociclib plus endocrine therapy (ET) vs ET alone in patients with intermediate-risk/high-risk hormone receptor (HR)–positive/HER2-negative early breast cancer (EBC) on the NATALEE trial?

Based on the final overall survival (OS) analysis of the phase III TROPiCs-02 trial, what tumor TROP-2 expression level by immunohistochemistry (IHC) (H score) would you use to identify patients with previously treated HR-positive/HER2-negative metastatic breast cancer most likely to benefit from sacituzumab govitecan?

When counseling older patients with metastatic HER2-positive breast cancer eligible for trastuzumab deruxtecan, how would you best describe results for the pooled analysis of the DESTINY-Breast01/02/03 trials by Krop and colleagues comparing efficacy and safety of trastuzumab deruxtecan in patients aged 65 years or older vs younger than 65 years with HER2-positive advanced breast cancer?